Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"

Ann Surg Oncol. 2025 Jan;32(1):503-504. doi: 10.1245/s10434-024-15944-z. Epub 2024 Aug 17.

Author

Magnus Glindvad Ahlström¹

Affiliation

¹ Residency in Clinical Microbiology, Department of Clinical Microbiology, Hvidovre Hospital, Hvidovre, Denmark. [email protected].

PMID: 39154155
DOI: 10.1245/s10434-024-15944-z

No abstract available

Publication types

Letter